Chi-Tai Kuo

Chi-Tai Kuo

Auto-generated profile, based on publicly available information

Chi-Tai Kuo

Cardiovascular Department, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan; College of Medicine, Chang Gung University, Taoyuan, Taiwan

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 September 2019 in Cardiovascular Diabetology
Verified
Journal Article
Open access
PDF file
YCYi-Hsin Chan
Yi-Hsin Chan
GCGwo-Jyh Chang
Gwo-Jyh Chang
YLYing-Ju Lai
Ying-Ju Lai
WCWei-Jan Chen
Wei-Jan Chen
SCShang-Hung Chang
Shang-Hung Chang
YYYung-Hsin Yeh
Yung-Hsin Yeh
Background: Insulin resistance (IR) is considered as a risk factor for atrial fibrillation (AF) even before diabetes develops. The pathophysiology and underlying mechanism are largely unclear. Methods: We investigated the corresponding mechanism in two IR models of rats fed 15-week high-fat (HFa) and high-fructose/cholesterol (HFr) diets. AF was evaluated and induced by burst atrial pacing. Isolated atrial myocytes were used for whole-cell patch clamp and calcium assessment. Ex vivo whole heart was used for optical mapping. Western blot and immunofluorescence were used for quantitative protein evaluation. Results: Both HFa and HFr rat atria were vulnerable to AF evaluated by burst atrial pacing. Isolated atrial myocytes from HFa and HFr rats revealed significantly increased sarcoplasmic reticulum calcium content and diastolic calcium sparks. Whole-heart mapping showed prolonged calcium transient duration, conduction velocity reduction, and repetitive ectopic focal discharge in HFa and HFr atria. Protein analysis revealed increased TGF-β1 and collagen expression; increased superoxide production; abnormal upregulation of calcium-homeostasis-related proteins, including oxidized CaMKIIδ, phosphorylated-phospholamban, phosphorylated-RyR-2, and sodium-calcium exchanger; and increased Rac1 activity in both HFa and HFr atria. We observed that inhibition of CaMKII suppressed AF in both HF and HFr diet-fed rats. In vitro palmitate-induced IR neonatal cardiomyocytes and atrial fibroblasts expressed significantly more TGF-β1 than did controls, suggesting paracrine and autocrine effects on both myocytes and fibroblasts. Conclusions: IR engenders both atrial structural remodeling and abnormal intracellular calcium homeostasis, contributing to increased AF susceptibility. The inhibition of CaMKII may be a potential therapeutic target for AF in insulin resistance.

17 April 2018 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
YCYi‐Hsin Chan
Yi‐Hsin Chan
LSLai‐Chu See
Lai‐Chu See
HTHui‐Tzu Tu
Hui‐Tzu Tu
YYYung‐Hsin Yeh
Yung‐Hsin Yeh
SCShang-Hung Chang
Shang-Hung Chang
CKChi‐Tai Kuo
Chi‐Tai Kuo
Background: Whether non–vitamin K antagonist oral anticoagulants ( NOAC s) are superior to warfarin among Asians with nonvalvular atrial fibrillation remains unclear. Methods and Results: In this nationwide retrospective cohort study collected from Taiwan National Health Insurance Research Database, there were 5843, 20 079, 27 777, and 19 375 nonvalvular atrial fibrillation patients taking apixaban, dabigatran, rivaroxaban and warfarin, respectively, from June 1, 2012 to December 31, 2016. Propensity‐score weighting was used to balance covariates across study groups. Patients were followed until the first occurrence of any efficacy or safety outcome or the end date of study. Hazard ratios (95% confidence intervals) comparing apixaban, dabigatran, and rivaroxaban with warfarin were: ischemic stroke/systemic embolism ( IS / SE ), 0.55 (0.43–0.69), 0.82 (0.68–0.98), and 0.81 (0.67–0.97); major bleeding, 0.41 (0.31–0.53), 0.65 (0.53–0.80), and 0.58 (0.46–0.72); and all‐cause mortality, 0.58 (0.51–0.66), 0.61 (0.54–0.68), and 0.57 (0.51–0.65). A total of 3623 (62%), 17 760 (88%), and 26 000 (94%) patients were taking low‐dose apixaban (2.5 mg twice daily), dabigatran (110 mg twice daily), and rivaroxaban (10–15 mg once daily), respectively. Similar to all‐dose NOAC s, all low‐dose NOAC s had lower risk of IS / SE , major bleeding, and mortality when compared with warfarin. In contrast to other standard‐dose NOAC s, apixaban was associated with lower risks of IS / SE (0.45 [0.31–0.65]), major bleeding (0.29 [0.18–0.46]), and mortality (0.23 [0.17–0.31]) than warfarin. Conclusions: All NOAC s were associated with lower risk of IS / SE , major bleeding, and mortality compared with warfarin in the largest real‐world practice among Asians with nonvalvular atrial fibrillation. All low‐dose NOAC s had lower risk of IS / SE , major bleeding, and mortality when compared with warfarin. Standard‐dose apixaban caused a lower risk of IS / SE , major bleeding, and mortality compared with warfarin.

1 September 2019 in Chest
Verified
Journal Article
Closed access
YCYi-Hsin Chan
Yi-Hsin Chan
HLHsin-Fu Lee
Hsin-Fu Lee
LSLai-Chu See
Lai-Chu See
HTHui-Tzu Tu
Hui-Tzu Tu
TCTze-Fan Chao
Tze-Fan Chao
GLGregory Y.H. Lip
Gregory Y.H. Lip

1 February 2016 in Stroke
Verified
Journal Article
Open access
PDF file
YCYi-Hsin Chan
Yi-Hsin Chan
KYKun-Chi Yen
Kun-Chi Yen
LSLai-Chu See
Lai-Chu See
SCShang-Hung Chang
Shang-Hung Chang
LWLung-Sheng Wu
Lung-Sheng Wu
CKChi-Tai Kuo
Chi-Tai Kuo
Background and Purpose—Whether dabigatran is associated with different risks of cardiovascular, bleeding events, and mortality from warfarin in Asian patients with nonvalvular atrial fibrillation remains unclear. Methods—We used the Taiwan National Health Insurance Research Database to obtain 9940 and 9913 nonvalvular atrial fibrillation patients taking dabigatran and warfarin, respectively, from June 1, 2012, to December 31, 2013, as the dynamic cohort. Inverse probability of treatment weighting using propensity scores was used to balance covariates across 2 study groups. Patients were followed up until the first occurrence of any study outcome or end date of study. Results—During a median follow-up period of 0.67 years, there were 526 outcomes for dabigatran group. The hazard ratios (95% confidence intervals) comparing dabigatran with warfarin (reference) were as follows: ischemic stroke, 0.62 (0.52–0.73; P<0.0001); myocardial infarction, 0.67 (0.43–1.05; P=0.0803); intracranial hemorrhage, 0.44 (0.32–0.60; P<0.0001); major gastrointestinal bleeding, 0.99 (0.66–1.49; P=0.9658); all hospitalized major bleeding, 0.58 (0.46–0.74; P<0.0001); and all-cause mortality, 0.45 (0.38–0.53; P<0.0001). Dabigatran did not increase the risk of myocardial infarction or major gastrointestinal bleeding in all age groups when compared with warfarin. Total 8772 patients (88%) took a 110-mg dose in dabigatran group. The magnitude of effect for each outcome of 110-mg was comparable with that of 150-mg dose in the subgroup analysis. Conclusions—In real-world practice, dabigatran was associated with a reduced risk of ischemic stroke, intracranial hemorrhage, all hospitalized major bleeding, and all-cause mortality compared with warfarin in Asian patients with nonvalvular atrial fibrillation. Dabigatran did not increase the risk of major gastrointestinal bleeding or myocardial infarction compared with warfarin.

1 November 2016 in JACC
Verified
Journal Article
Open access
YCYi-Hsin Chan
Yi-Hsin Chan
YYYung-Hsin Yeh
Yung-Hsin Yeh
LSLai-Chu See
Lai-Chu See
CWChun-Li Wang
Chun-Li Wang
SCShang-Hung Chang
Shang-Hung Chang
CKChi-Tai Kuo
Chi-Tai Kuo
Whether dabigatran is associated with a lower risk of acute kidney injury (AKI) in patients with nonvalvular atrial fibrillation (NVAF) remains unknown. The authors compared the risk of AKI in Asians with NVAF who were prescribed dabigatran versus warfarin. The authors analyzed patients enrolled in the Taiwan nationwide retrospective cohort study from June 1, 2012, to December 31, 2013. Dabigatran and warfarin were taken by 7,702 and 7,885 NVAF patients without a history of chronic kidney disease (CKD) and 2,256 and 2,089 NVAF patients with a history of CKD, respectively. A propensity-score weighted method was used to balance covariates across study groups. A total of 6,762 (88%) and 940 (12%) CKD-free patients and 2,025 (90%) and 231 (10%) CKD patients took dabigatran 110 mg and 150 mg twice daily, respectively. Dabigatran was associated with a lower risk of AKI than warfarin for either the CKD-free (hazard ratio [HR]: 0.62; 95% confidence interval [CI]: 0.49 to 0.77; p < 0.001) or CKD (HR: 0.56; 95% CI: 0.46 to 0.69; p < 0.001) cohort. As the increment in CHA2DS2-VASc score (a risk score based on congestive heart failure, hypertension, age 75 years or older, diabetes mellitus, previous stroke/transient ischemic attack, vascular disease, aged 65 to 74 years, and female sex) increased from 0/1 to 6+ points, the incidence of AKI for the dabigatran group was relatively stable (1.87% to 2.91% per year for the CKD-free cohort; 7.31% to 13.15% per year for the CKD cohort) but increased obviously for patients taking warfarin for either CKD-free (2.00% to 6.16% per year) or CKD cohorts (6.82 to 26.03% per year). The warfarin group had a significantly higher annual risk of AKI than the dabigatran group for those with a high CHA2DS2-VASc score (≥4 for the CKD-free cohort and ≥3 for the CKD cohort). Subgroup analysis revealed that among dabigatran users, those taking either low-dose or standard-dose dabigatran, those with a warfarin-naïve or warfarin-experienced history, those with or without diabetes, and those with CHA2DS2-VASc ≥4 or HAS-BLED ≥3 (risk score based on hypertension, abnormal renal and liver function, stroke, prior major bleeding, labile international normalized ratios, age 65 years or older, drugs or alcohol usage history) all had a lower risk of AKI than those taking warfarin. Among Asians with NVAF, dabigatran is associated with a lower risk of AKI than warfarin.

1 August 2018 in International Journal of Cardiology
Verified
Journal Article
Closed access
YCYi-Hsin Chan
Yi-Hsin Chan
YYYung-Hsin Yeh
Yung-Hsin Yeh
MHMei-Yun Hsieh
Mei-Yun Hsieh
CCChia-Yu Chang
Chia-Yu Chang
HTHui-Tzu Tu
Hui-Tzu Tu
CKChi-Tai Kuo
Chi-Tai Kuo